Article

The function of the protein tyrosine phosphatase SHP-1 in cancer.

Program in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worchester, MA 01605, USA.
Gene (Impact Factor: 2.08). 04/2003; 306:1-12. DOI: 10.1016/S0378-1119(03)00400-1
Source: PubMed

ABSTRACT SHP-1, an SH2 domain-containing protein tyrosine phosphatase, is primarily expressed in hematopoietic cells and behaves as a key regulator controlling intracellular phosphotyrosine levels in lymphocytes. SHP-1 has been proposed as a candidate tumor suppressor gene in lymphoma, leukemia and other cancers, as it functions as an antagonist to the growth-promoting and oncogenic potentials of tyrosine kinase. The decreased levels of SHP-1 protein and SHP-1 mRNA observed in various leukemia and lymphoma cell lines have been attributed to either the methylation of the promoter region of the SHP-1 gene or the post-transcriptional block of SHP-1 protein synthesis. In contrast, SHP-1 protein is normally or over-expressed in some non-lymphocytic cell lines, such as prostate cancer, ovarian cancer and breast cancer cell lines. SHP-1 expression also is decreased in some breast cancer cell lines with negative expression of estrogen receptor as well as some prostate and colorectal cancer cell lines. These data suggest that SHP-1 can play either negative or positive roles in regulating signal transduction pathways. Dysfunction in SHP-1 regulation can cause abnormal cell growth and induce different kinds of cancers. In this paper, we summarize recent studies on the expression and regulation of SHP-1 protein and its pathological function in the development of lymphoma, leukemia and other cancers.

0 Followers
 · 
96 Views
  • Source
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary renal cell carcinoma (RCC) in Eker rats results from an inherited insertional mutation in the Tsc2 tumor suppressor gene and provides a valuable experimental model to characterize the function of the Tsc2 gene product, tuberin in vivo. The Tsc2 mutation predisposes the Eker rat to develop renal tumors at an early age. The exact mechanism of Tsc2 mediated tumor suppression is not known, however, there is evidence that it is most likely mediated by changes in cell cycle regulation via the PI3K/Akt pathway. The present study was designed to identify if gene expression was different in Tsc2 heterozygous mutant rat kidney compared to wild-type and if any of those differences are associated with tumorigenesis. cDNA microarray analysis of the untreated Tsc2 (+/−) mutant Long Evans (Eker) rat was compared to the Tsc2 (+/+) wild-type Long Evans rat to search for patterns that might be indicative of the intrinsic role of Tsc2. Of 4395 genes queried, 3.2% were significantly altered in kidneys from heterozygous mutant rats, of which 110 (76%) were up-regulated and 34 (24%) were down-regulated relative to the wild-type. The genes with altered expression belonged to the functional categories of cell cycle regulation, cell proliferation, cell adhesion and endocytosis. Many of these genes appear to be directly or indirectly regulated by the PI3K/Akt pathway. In addition to the PI3K/Akt pathway, other signaling pathways were also differentially expressed in Tsc2 mutant Eker rat kidneys compared to wild-type rats. The gene expression profiles of the Tsc2 heterozygous mutant and wild-type animals highlights new pathways for investigation that may be associated with the tumorigenic activity of tuberin loss and correlate with the enhanced susceptibility of the Tsc2 mutant animal’s tendency to develop renal cell carcinoma.
    Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 05/2004; 549(1-2):213-224. DOI:10.1016/S0027-5107(04)00068-5 · 4.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In our study, the region between positions 16052 and 16390 in HVI and the region between 72 and 387 in HVII were completely sequenced. 40 different haplotypes resulting from 174 polymorphic positions in HVI and 62 in HVII were observed. Nucleotide substitutions are the predominate polymorphisms, and at least 79.6% and 69.3% of the substitutions in HVI and HVII are transitions, respectfully. The most prevalent transitions are Cs substituted for Ts and Ts substituted for Cs in both HVI and HVII. A condition of sequence heteroplasmy were found in two case at nt16209 and 16245. The T to C transition at nt 16190 was observed in 25 subject (53%) in this study.
    10th Malaysia Genetics Congress, Advances in Genetics Biotechnology and Genomics, Malaysia; 12/2013

Full-text

Download
38 Downloads
Available from
Oct 2, 2014